2022 World Conference on Lung Cancer (Posters)-P1.13-01. Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma

P1.13-01. Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma

Back to course

Pdf Summary

A study presented at the 2022 World Conference on Lung Cancer suggests that preoperative chemotherapy can induce epithelial-mesenchymal transition (EMT) in patients with malignant pleural mesothelioma (MPM), leading to reduced survival rates after surgery. The researchers analyzed the perioperative course of 127 patients who underwent pleurectomy/decortication for MPM over a 5-year period. They found that EMT occurred in 28.6% of patients who received neoadjuvant chemotherapy, compared to only one case in patients who underwent upfront surgery. EMT was not associated with the method of biopsy or the extent of disease. Overall survival was significantly reduced in patients who received neoadjuvant chemotherapy and exhibited EMT, as well as in those with less than 80% epithelial component in their post-resectional histology. However, there was no difference in overall survival between patients who received neoadjuvant chemotherapy and those who had upfront surgery. The study suggests that the risk of EMT and its impact on survival should be considered when deciding on the initial treatment modality for resectable mesothelioma. Further research comparing neoadjuvant and adjuvant chemotherapy in early-stage epithelial disease is needed.

Asset Subtitle

Luigi Ventura, United Kingdom

Meta Tag

Speaker Luigi Ventura, United Kingdom

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

Keywords

preoperative chemotherapy

epithelial-mesenchymal transition

malignant pleural mesothelioma

survival rates

pleurectomy/decortication

neoadjuvant chemotherapy

upfront surgery

biopsy

extent of disease

overall survival